New fibroid Drug's hidden danger? study probes blood clot risk
NCT ID NCT07173127
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether Ryeqo, a newer hormone treatment for uterine fibroids and endometriosis, increases the risk of dangerous blood clots. Researchers will take blood samples from 30 women before they start Ryeqo and again after 3 months of treatment. The goal is to measure changes in clotting markers to better understand the drug's safety.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UTERINE FIBROID are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpitaux Universitaires de Genève
RECRUITINGGeneva, Canton of Geneva, 1205, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Stiffness check could boost fibroid treatment success
- 700 women followed for over a decade to see which fibroid treatments last longest
- New study aims to predict which fibroids respond best to Non-Invasive ultrasound treatment
- New particles aim to shrink fibroids without surgery
- Acupuncture before surgery may steady blood pressure in hysterectomy patients
- Study examines pregnancy after fibroid surgery